Investor ADAR1 Partners, LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by ADAR1 Partners, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-04-05 13G IBIO / iBio, Inc. 789,293
2024-03-14 13G FIXX / Homology Medicines, Inc. 3,120,824
2024-02-23 13G AVRO / AVROBIO, Inc. 3,276,498
2024-02-22 13G MACK / Merrimack Pharmaceuticals, Inc. 902,350
2024-01-31 13G CLRB / Cellectar Biosciences, Inc. 1,824,063
2023-07-20 13G SURF / Surface Oncology Inc 3,183,242
2022-09-30 13G IPOF / Social Capital Hedosophia Holdings Corp VI - Class A 7,688,476
2022-07-27 13G FST / FAST Acquisition Corp - Class A 1,341,700